Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 24

1.

Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis.

Hobbs BD, de Jong K, Lamontagne M, Bossé Y, Shrine N, Artigas MS, Wain LV, Hall IP, Jackson VE, Wyss AB, London SJ, North KE, Franceschini N, Strachan DP, Beaty TH, Hokanson JE, Crapo JD, Castaldi PJ, Chase RP, Bartz TM, Heckbert SR, Psaty BM, Gharib SA, Zanen P, Lammers JW, Oudkerk M, Groen HJ, Locantore N, Tal-Singer R, Rennard SI, Vestbo J, Timens W, Paré PD, Latourelle JC, Dupuis J, O'Connor GT, Wilk JB, Kim WJ, Lee MK, Oh YM, Vonk JM, de Koning HJ, Leng S, Belinsky SA, Tesfaigzi Y, Manichaikul A, Wang XQ, Rich SS, Barr RG, Sparrow D, Litonjua AA, Bakke P, Gulsvik A, Lahousse L, Brusselle GG, Stricker BH, Uitterlinden AG, Ampleford EJ, Bleecker ER, Woodruff PG, Meyers DA, Qiao D, Lomas DA, Yim JJ, Kim DK, Hawrylkiewicz I, Sliwinski P, Hardin M, Fingerlin TE, Schwartz DA, Postma DS, MacNee W, Tobin MD, Silverman EK, Boezen HM, Cho MH; COPDGene Investigators.; ECLIPSE Investigators.; LifeLines Investigators.; SPIROMICS Research Group.; International COPD Genetics Network Investigators.; UK BiLEVE Investigators.; International COPD Genetics Consortium..

Nat Genet. 2017 Mar;49(3):426-432. doi: 10.1038/ng.3752.

PMID:
28166215
2.

Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD.

Kreindler JL, Watkins ML, Lettis S, Tal-Singer R, Locantore N.

BMJ Open Respir Res. 2016 Sep 8;3(1):e000151. doi: 10.1136/bmjresp-2016-000151.

3.

A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol.

Pascoe SJ, Lipson DA, Locantore N, Barnacle H, Brealey N, Mohindra R, Dransfield MT, Pavord I, Barnes N.

Eur Respir J. 2016 Aug;48(2):320-30. doi: 10.1183/13993003.02165-2015.

PMID:
27418551
4.

Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model.

Briggs A, Baker T, Risebrough NA, Chambers M, Gonzalez-McQuire S, Ismaila AS, Exuzides A, Colby C, Tabberer M, Muellerova H, Locantore N, Rutten van-Mölken MP, Lomas DA.

Med Decis Making. 2016 Jun 17. pii: 0272989X16653118. [Epub ahead of print]

PMID:
27317436
5.

Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD.

Pavord ID, Lettis S, Locantore N, Pascoe S, Jones PW, Wedzicha JA, Barnes NC.

Thorax. 2016 Feb;71(2):118-25. doi: 10.1136/thoraxjnl-2015-207021.

6.

Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study.

Exuzides A, Colby C, Briggs A, Lomas DA, Rutten van-Mölken M, Tabberer M, Chambers M, Muellerova H, Locantore N, Risebrough NA, Ismaila AS, Gonzalez-McQuire S.

Med Decis Making. 2015 Oct 8. pii: 0272989X15610781. [Epub ahead of print]

PMID:
26449490
7.

Blood eosinophil counts as markers of response to inhaled corticosteroids in COPD?--Authors' reply.

Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord I.

Lancet Respir Med. 2015 Aug;3(8):e27. doi: 10.1016/S2213-2600(15)00259-3. No abstract available.

PMID:
26282479
9.

Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis.

Rennard SI, Locantore N, Delafont B, Tal-Singer R, Silverman EK, Vestbo J, Miller BE, Bakke P, Celli B, Calverley PM, Coxson H, Crim C, Edwards LD, Lomas DA, MacNee W, Wouters EF, Yates JC, Coca I, Agustí A; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints..

Ann Am Thorac Soc. 2015 Mar;12(3):303-12. doi: 10.1513/AnnalsATS.201403-125OC.

PMID:
25642832
10.

Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort.

Müllerova H, Maselli DJ, Locantore N, Vestbo J, Hurst JR, Wedzicha JA, Bakke P, Agusti A, Anzueto A; ECLIPSE Investigators..

Chest. 2015 Apr;147(4):999-1007. doi: 10.1378/chest.14-0655.

PMID:
25356881
11.

Eosinophilic inflammation in COPD: prevalence and clinical characteristics.

Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R; ECLIPSE investigators..

Eur Respir J. 2014 Dec;44(6):1697-700. doi: 10.1183/09031936.00162414. No abstract available.

12.

A diVIsive Shuffling Approach (VIStA) for gene expression analysis to identify subtypes in Chronic Obstructive Pulmonary Disease.

Menche J, Sharma A, Cho MH, Mayer RJ, Rennard SI, Celli B, Miller BE, Locantore N, Tal-Singer R, Ghosh S, Larminie C, Bradley G, Riley JH, Agusti A, Silverman EK, Barabási AL.

BMC Syst Biol. 2014;8 Suppl 2:S8. doi: 10.1186/1752-0509-8-S2-S8.

13.

Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.

Dransfield MT, Feldman G, Korenblat P, LaForce CF, Locantore N, Pistolesi M, Watkins ML, Crim C, Martinez FJ.

Respir Med. 2014 Aug;108(8):1171-9. doi: 10.1016/j.rmed.2014.05.008.

14.

Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team.

Vestbo J, Agusti A, Wouters EF, Bakke P, Calverley PM, Celli B, Coxson H, Crim C, Edwards LD, Locantore N, Lomas DA, MacNee W, Miller B, Rennard SI, Silverman EK, Yates JC, Tal-Singer R; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Study Investigators..

Am J Respir Crit Care Med. 2014 May 1;189(9):1022-30. doi: 10.1164/rccm.201311-2006PP.

PMID:
24552242
15.

Lessons from ECLIPSE: a review of COPD biomarkers.

Faner R, Tal-Singer R, Riley JH, Celli B, Vestbo J, MacNee W, Bakke P, Calverley PM, Coxson H, Crim C, Edwards LD, Locantore N, Lomas DA, Miller BE, Rennard SI, Wouters EF, Yates JC, Silverman EK, Agusti A; ECLIPSE Study Investigators..

Thorax. 2014 Jul;69(7):666-72. doi: 10.1136/thoraxjnl-2013-204778. Review.

PMID:
24310110
16.

A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD.

Agustí A, de Teresa L, De Backer W, Zvarich MT, Locantore N, Barnes N, Bourbeau J, Crim C.

Eur Respir J. 2014 Mar;43(3):763-72. doi: 10.1183/09031936.00054213.

17.

Factors associated with change in exacerbation frequency in COPD.

Donaldson GC, Müllerova H, Locantore N, Hurst JR, Calverley PM, Vestbo J, Anzueto A, Wedzicha JA.

Respir Res. 2013 Jul 30;14:79. doi: 10.1186/1465-9921-14-79.

18.

A new class of bronchodilator improves lung function in COPD: a trial with GSK961081.

Wielders PL, Ludwig-Sengpiel A, Locantore N, Baggen S, Chan R, Riley JH.

Eur Respir J. 2013 Oct;42(4):972-81. doi: 10.1183/09031936.00165712.

19.

A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics.

Hodsman P, Ashman C, Cahn A, De Boever E, Locantore N, Serone A, Pouliquen I.

Br J Clin Pharmacol. 2013 Jan;75(1):118-28. doi: 10.1111/j.1365-2125.2012.04334.x.

20.

Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease.

Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P, Calverley P, Coxson H, Crim C, Edwards LD, Lomas DA, Duvoix A, MacNee W, Rennard S, Silverman E, Vestbo J, Wouters E, Agustí A; ECLIPSE Investigators..

Am J Respir Crit Care Med. 2012 May 15;185(10):1065-72. doi: 10.1164/rccm.201110-1792OC.

PMID:
22427534
Items per page

Supplemental Content

Loading ...
Support Center